Clinical Trials Sponsored by Mabspace Biosciences (Suzhou) Co., Ltd.

Total 811 results

Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque Psoriasis

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

Advanced Malignant Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects

Pulmonary Fibrosis | Tumor

Australia
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Primary Hypercholesterolaemia and Mixed Dyslipidemia

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

6MW3511 in Patients With Advanced Solid Tumor

Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

Lymphoma
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study of 6MW3211 in Patients With Renal Cancer

Advanced Clear Cell Renal Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Intrahepatic Cholangiocarcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Gastric or Esophagogastric Junction Adenocarcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Advanced Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Clinical Study of JS007 in Patients With Advanced Solid Tumors

Patients With Advanced Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

Advanced Lung Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19

Covid19

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

Melanoma | Breast Cancer | Lung Cance

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection

Asthma | Atopic Dermatitis | COPD

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma (JS001)

Metastatic Melanoma | Unresectable Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

Advanced Hepatocellular Carcinoma (HCC)

China, Singapore
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Stage II-III Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Hyperlipemia

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects

COVID-19

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults (MW031)

Osteoporosis, Postmenopausal

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Advanced Melanoma | Kidney Cancer Stage Iv

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

Bladder Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers

Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005

China
Walvax Biotechnology Co., Ltd.
Abogen Biosciences Co. Ltd.; Yuxi Walvax Biotechnology Co., Ltd.

Recruiting

A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above

COVID-19 | SARS-CoV-2

Indonesia, Mexico
Fudan University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Suzhou Immunofoco Biotechnology Co., Ltd
Changhai Hospital

Recruiting

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Gastric Cancer | Pancreatic Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Ovarian Carcinoma

China
RenJi Hospital
Suzhou SinoMed Biomaterials Co., Ltd

Active, not recruiting

Exploratory Study on Safety of PEEK Knee Prosthesis

Osteoarthritis of the Knee | Rheumatoid Arthritis of Knee

China
Sichuan University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Stage IV NSCLC

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Suspended

SY007 in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

A Drug Interaction Study of SY-004 Capsules in Healthy Subjects

Type 2 Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Huashan Hospital
Sumitomo Pharmaceuticals (Suzhou) Co. Ltd

Unknown

WGS-guided Tracking and Infection Control Measures of CRKP

Klebsiella Pneumoniae Infection

China
Peking University
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-009 in Healthy Subjects

Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-008 in Healthy Subjects

Diabetes

China
ISU Abxis Co., Ltd.
Catalyst Biosciences

Completed

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

Hemophilia B

Korea, Republic of
DK Medical Technology (Suzhou) Co., Ltd.
Core Medical (Beijing) Co., Ltd.

Active, not recruiting

A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary Small Vessel Disease

Coronary Small Vessel Disease

China
DK Medical Technology (Suzhou) Co., Ltd.
Core Medical (Beijing) Co., Ltd.

Active, not recruiting

A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent Restenosis

Coronary In-stent Restenosis

China
Fudan University
GeneQuantum Healthcare (Suzhou) Co., Ltd.

Recruiting

GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

Advanced/ Metastatic Her-2 Positive Breast Cancer

China
Jiesi Yingda Pharmaceutical Technology (Suzhou)...

Recruiting

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer (VIC-1911)

Advanced Non-small Cell Lung Cancer

China

Clinical Trials Sponsored by Mabspace Biosciences (Suzhou) Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations